U.S. Markets closed
  • S&P Futures

    4,272.00
    -69.50 (-1.60%)
     
  • Dow Futures

    33,583.00
    -472.00 (-1.39%)
     
  • Nasdaq Futures

    13,885.50
    -273.00 (-1.93%)
     
  • Russell 2000 Futures

    1,932.40
    -40.30 (-2.04%)
     
  • Crude Oil

    86.52
    -0.83 (-0.95%)
     
  • Gold

    1,814.80
    -14.90 (-0.81%)
     
  • Silver

    23.33
    -0.47 (-1.98%)
     
  • EUR/USD

    1.1225
    -0.0020 (-0.1796%)
     
  • 10-Yr Bond

    1.8480
    +0.0650 (+3.65%)
     
  • Vix

    31.96
    +0.80 (+2.57%)
     
  • GBP/USD

    1.3437
    -0.0026 (-0.1895%)
     
  • USD/JPY

    114.6120
    -0.0480 (-0.0419%)
     
  • BTC-USD

    35,776.59
    -1,569.11 (-4.20%)
     
  • CMC Crypto 200

    814.04
    -41.77 (-4.88%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    26,186.74
    -824.56 (-3.05%)
     

Strong week for Nutriband (NASDAQ:NTRB) shareholders doesn't alleviate pain of three-year loss

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • NTRB
  • NTRBW

Nutriband Inc. (NASDAQ:NTRB) has rebounded strongly over the last week, with the share price soaring 54%. But over the last three years we've seen a quite serious decline. Indeed, the share price is down a tragic 66% in the last three years. So it is really good to see an improvement. While many would remain nervous, there could be further gains if the business can put its best foot forward.

On a more encouraging note the company has added US$23m to its market cap in just the last 7 days, so let's see if we can determine what's driven the three-year loss for shareholders.

Check out our latest analysis for Nutriband

Nutriband isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last three years, Nutriband saw its revenue grow by 68% per year, compound. That's well above most other pre-profit companies. In contrast, the share price is down 18% compound, over three years - disappointing by most standards. This could mean hype has come out of the stock because the losses are concerning investors. But a share price drop of that magnitude could well signal that the market is overly negative on the stock.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

We're pleased to report that Nutriband rewarded shareholders with a total shareholder return of 29% over the last year. What is absolutely clear is that is far preferable to the dismal 18% average annual loss suffered over the last three years. The optimist would say this is evidence that the stock has bottomed, and better days lie ahead. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 6 warning signs for Nutriband (2 shouldn't be ignored) that you should be aware of.

But note: Nutriband may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.